Canada - English - Health Canada

merck canada inc - indinavir (indinavir sulfate) - capsule - 300mg - indinavir (indinavir sulfate) 300mg - hiv protease inhibitors

United States - English - NLM (National Library of Medicine)

rebel distributors corp - indinavir sulfate (unii: 771h53976q) (indinavir - unii:5w6ya9pkkh) - indinavir 400 mg - crixivan in combination with antiretroviral agents is indicated for the treatment of hiv infection. this indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of aids-defining illnesses or death; 2) a prolonged suppression of hiv rna. in all clinical studies, with the exception of actg 320, the amplicor hiv monitor assay was used to determine the level of circulating hiv rna in serum. this is an experimental use of the assay. hiv rna results should not be directly compared to results from other trials using different hiv rna assays or using other sample sources. study actg 320 was a multicenter, randomized, double-blind clinical endpoint trial to compare the effect of crixivan in combination with zidovudine and lamivudine with that of zidovudine plus lamivudine on the progression to an aids-defining illness (adi) or death. patients were protease inhibitor and lamivudine naive and zidovudine experienced, with cd4 cell counts of ≤200 cells/mm3

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - indinavir sulfate (unii: 771h53976q) (indinavir - unii:5w6ya9pkkh) - indinavir 400 mg - crixivan in combination with antiretroviral agents is indicated for the treatment of hiv infection. this indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of aids-defining illnesses or death; 2) a prolonged suppression of hiv rna. in all clinical studies, with the exception of actg 320, the amplicor hiv monitor assay was used to determine the level of circulating hiv rna in serum. this is an experimental use of the assay. hiv rna results should not be directly compared to results from other trials using different hiv rna assays or using other sample sources. study actg 320 was a multicenter, randomized, double-blind clinical endpoint trial to compare the effect of crixivan in combination with zidovudine and lamivudine with that of zidovudine plus lamivudine on the progression to an aids-defining illness (adi) or death. patients were protease inhibitor and lamivudine naive and zidovudine experienced, with cd4 cell counts of ≤200 cells/mm3

United States - English - NLM (National Library of Medicine)

stat rx usa llc - indinavir sulfate (unii: 771h53976q) (indinavir anhydrous - unii:9mg78x43zt) - indinavir anhydrous 400 mg - crixivan in combination with antiretroviral agents is indicated for the treatment of hiv infection. this indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of aids-defining illnesses or death; 2) a prolonged suppression of hiv rna. in all clinical studies, with the exception of actg 320, the amplicor hiv monitor assay was used to determine the level of circulating hiv rna in serum. this is an experimental use of the assay. hiv rna results should not be directly compared to results from other trials using different hiv rna assays or using other sample sources. study actg 320 was a multicenter, randomized, double-blind clinical endpoint trial to compare the effect of crixivan in combination with zidovudine and lamivudine with that of zidovudine plus lamivudine on the progression to an aids-defining illness (adi) or death. patients were protease inhibitor and lamivudine naive and zidovudine experienced, with cd4 cell counts of ≤200 cells/mm3

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - indinavir sulfate (unii: 771h53976q) (indinavir anhydrous - unii:9mg78x43zt) - indinavir anhydrous 100 mg - crixivan in combination with antiretroviral agents is indicated for the treatment of hiv infection. this indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of aids-defining illnesses or death; 2) a prolonged suppression of hiv rna. in all clinical studies, with the exception of actg 320, the amplicor hiv monitor assay was used to determine the level of circulating hiv rna in serum. this is an experimental use of the assay. hiv rna results should not be directly compared to results from other trials using different hiv rna assays or using other sample sources. study actg 320 was a multicenter, randomized, double-blind clinical endpoint trial to compare the effect of crixivan in combination with zidovudine and lamivudine with that of zidovudine plus lamivudine on the progression to an aids-defining illness (adi) or death. patients were protease inhibitor and lamivudine naive and zidovudine experienced, with cd4 cell counts of ≤200 cells/mm3

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - indinavir sulfate (unii: 771h53976q) (indinavir anhydrous - unii:9mg78x43zt) - indinavir anhydrous 400 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sirolimus -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - women: moderately severe to severe signs of androgenisation. moderately severe/severe forms of hirsutism; moderately severe/severe androgen dependent loss of scalp hair (moderately severe/severe androgenic alopecia); moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenisation. apo-cyproterone acetate 50mg inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused by either increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment. if apo-cyproterone acetate 50mg is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of child bearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular menstruation. men: reduction of drive in sexual deviations. apo-cyproterone acetate 50mg reduces the force of the sexual urge in men with sexual deviations. whilst under treatment the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a prerequisite for therapy is the desire by the patient for treatment. apo-cyproterone acetate 50mg should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social reorientation. inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - vemurafenib, quantity: 800 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; magnesium stearate; iron oxide red; hyprolose; purified talc; polyvinyl alcohol; macrogol 3350 - zelboraf is indicated for the treatment of unresectable stage iiic or stage iv metastatic melanoma positive for a braf v600 mutation.